Martin Auster's questions to WAVE Life Sciences Ltd (WVE) leadership • Q2 2025
Question
Martin Auster of Raymond James followed up on the WVE-007 program, asking if Activin E reduction data from cohort two would influence the size of cohort three and whether that could potentially shift the planned Q1 2026 data disclosure timeline for cohort three.
Answer
President & CEO Paul Bolno stated that they would expect a similar approach for cohort three as they took for cohort two, but this would not shift the timeline for delivering the 400 mg cohort data in 2026. He emphasized the study was well-designed to assess the dose response between 240 mg and 400 mg and that recruitment has been incredibly efficient, keeping all data readouts on track.